New drug and cellular therapies have the potential to transform clinical outcomes in patients with blood cancer and solid tumours. Their adoption in routine clinical practice is pivotally dependent on the rapid delivery of safety and efficacy trials which play in central role in ensuring accelerated approval. The proliferation of novel therapies coupled with the increasing importance of genomic stratification mandates a fundamental reappraisal of trial delivery models if we are to optimise trial delivery to the benefit of both patients and the global biopharmaceutical sector. In this webinar two innovative and highly effective national trial delivery models with the potential to accelerate trial set up and recruitment and in the process exploit the strategic opportunities within the UK Life Sciences sector will be discussed